Joshua Wigdahl, PA
Physician Assistant · Derby, KSNPI 1457729097
Payments from drug & device makers
Across 407 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$930
- Novo Nordisk$789
- Lilly USA, LLC$593
- AstraZeneca$534
- Amgen$420
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$355
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,344100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $930 |
| Novo Nordisk | 53 | $789 |
| Lilly USA, LLC | 42 | $593 |
| AstraZeneca | 33 | $534 |
| Amgen | 23 | $420 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $355 |
| GSK | 18 | $330 |
| Astellas Pharma US Inc | 13 | $236 |
| Pfizer | 20 | $199 |
| Bayer | 12 | $189 |
| Johnson & Johnson | 11 | $179 |
| Merck | 11 | $169 |
| Abbott | 10 | $167 |
| Sanofi-aventis U.S. LLC | 8 | $133 |
| Amarin Pharma, Inc. | 7 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $85 |
| Exact Sciences | 4 | $58 |
| Boehringer Ingelheim | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Insulet Corporation | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Medtronic | 2 | $41 |
| Lundbeck LLC | 2 | $41 |
| Eisai Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Abiomed | 1 | $29 |
| Seqirus USA Inc | 1 | $24 |
| Bausch Health US, LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Edwards Lifesciences | 1 | $12 |
How this compares
$6,344 in reported general payments places this provider in the 90th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $37,999 |
| FarxigaDapagliflozin Propanediol | 40 | $37,396 |
| MounjaroTirzepatide | 32 | $35,148 |
| TrulicityDulaglutide | 14 | $22,867 |
| EliquisApixaban | 37 | $21,470 |
| JardianceEmpagliflozin | 15 | $10,387 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $7,842 |
| SavellaMilnacipran Hcl | 16 | $7,615 |
| Dexlansoprazole DrDexlansoprazole | 23 | $6,259 |
| BelsomraSuvorexant | 14 | $5,807 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,765 |
| MyrbetriqMirabegron | 12 | $5,419 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $2,591 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,242 |
| Pregabalin | 37 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $593 | $58,01546 claims |
| Novo NordiskOzempic | $789 | $37,99936 claims |
| AstraZenecaFarxiga | $534 | $37,39640 claims |
| PfizerEliquis | $199 | $21,47037 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $56 | $16,15227 claims |
| AbbVieSavella, Synthroid | $930 | $8,48034 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $133 | $7,84216 claims |
| MerckBelsomra | $169 | $5,80714 claims |
| Astellas Pharma US IncMyrbetriq | $236 | $5,41912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Derby
- Erica HickersonDerby$8K
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Melissa WilkesFort Riley$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.